U.S. FDA panel backs approval for Indivior opioid addiction drug

(Reuters) – Indivior Plc's experimental drug to treat opioid addiction should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.
Original Article

more recommended stories